Table of Contents
You may have seen headlines saying six popular peptides were ‘approved.’ That is not what happened. The October 2026 change concerns limited federal enforcement discretion for certain compounded products, not FDA drug approval.
Which six peptides?
The HHS policy names BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. In July 2026, an FDA pharmacy compounding advisory committee voted to recommend them for possible inclusion on the section 503A bulk substances list. A committee recommendation is not a final FDA decision.
What HHS announced in October
On October 28, 2026, HHS issued an interim enforcement-discretion policy, followed by an October 30 Federal Register notice. Under specified conditions, HHS says it does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities, or licensed physicians compounding the named substances while rulemaking continues.
The conditions matter
Among other requirements are a valid patient-specific prescription, a qualified manufacturer, appropriate lot-specific testing and Certificate of Analysis, adverse-event reporting, a single active pharmaceutical ingredient, and the exact substance and route described in the policy. The policy does not automatically cover multi-peptide blends, every formulation, or every seller.
What this does not prove
None of the six peptides is FDA-approved as a drug. Compounded drugs are not evaluated through FDA’s usual
approval process for safety, effectiveness and quality before marketing. Evidence of benefit is different for each
peptide and remains limited for many popular uses.
Questions for our team
At The Re/ Clinic in Sandy, Utah, we can discuss the evidence, risks, product sourcing and whether any prescribed
option fits current rules and your individual medical situation.
Schedule a consultation with The Re/ Clinic in Sandy, Utah, to discuss peptide questions, evidence and eligibility.
FDA Disclaimer: Muse cell products, including Dezawa MuseCells®, have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. The information in this article is for education only and is not medical advice. Individual results vary, and no specific outcome is promised or guaranteed. Talk with your primary care provider before starting any stem cell therapy.
Utah Notice: This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing a stem cell therapy. (Utah Code 58-1-512).





